• Apicidin Disrupts Oocyte Maturation and Histone Acetylation

  2026-09-04

  The 2026 reference study identifies a reproductive-toxicity mechanism for Apicidin by linking impaired oocyte meiotic maturation with spindle, chromosome, actin, DNA-damage, and histone-acetylation abnormalities. Its findings expand evaluation of this histone deacetylase inhibitor beyond somatic-cell toxicity and emphasize the need to distinguish epigenetic activity from reproductive safety.

• MiR-3180 Rewires Lipid Metabolism in HCC

  2026-09-03

  Hong et al. identify miR-3180 as a coordinated regulator of fatty-acid synthesis and uptake in hepatocellular carcinoma by targeting SCD1 and CD36. The study links reduced miR-3180 expression with aggressive tumor behavior and poorer prognosis, while integrating tissue analyses, molecular assays, lipid phenotyping, cell models, and xenograft validation.

• Toremifene Workflows for Prostate Cancer Research

  2026-09-03

  Toremifene is a practical selective estrogen-receptor modulator for linking hormone-response measurements with cell growth, migration, invasion, and calcium-signaling assays. This workflow guide shows how to build concentration-response studies, interpret the TSPAN18-STIM1 metastasis mechanism, and troubleshoot experiments without implying that Toremifene directly targets that pathway.

• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-09-02

  The Anti-HMGB1 Rabbit Monoclonal Antibody, SKU MA3057, supports targeted HMGB1 detection in human, mouse, and rat research samples by Western blot, immunohistochemistry, and flow cytometry. It is an unconjugated research reagent and should not be used for diagnosis, therapy, or other medical purposes.

• LY2603618: Redox Logic for Chk1 Assays

  2026-09-02

  LY2603618 is a selective Chk1 inhibitor for studying checkpoint failure, DNA damage, and chemotherapy response. This guide adds a redox and deoxynucleotide-pool framework to conventional G2/M and γH2AX assays, helping researchers design more informative experiments.

• CUDC-907 Dual PI3K/HDAC Workflow Guide

  2026-09-01

  CUDC-907 provides a defined starting point for cell-based studies that require concurrent PI3K/AKT signaling pathway inhibition and histone deacetylase (HDAC) inhibition. This dossier-based guidance supports controlled in vitro research and assay development, but the compound is not intended for diagnostic, clinical, or therapeutic use.

• Rhodamine 123 (chloride) Assay Guide

  2026-09-01

  Rhodamine 123 (chloride) enables interpretation-focused analysis of P-glycoprotein activity, cellular uptake, and membrane transport. This guide connects dye behavior with ABC transporter biology while showing how to avoid confusing ABCB1, OATP1A2, and ABCG2 signals.

• Streptavidin-FITC for Bacterial Adhesion Assays

  2026-08-31

  Use Streptavidin-FITC to convert biotinylated antibodies, probes, and cell-associated targets into measurable fluorescence across adhesion, imaging, and flow workflows. This guide connects the ST3GAL1–Fusobacterium nucleatum findings with practical assay design, controls, optimization, and troubleshooting.

• U 46619: From TP Signaling to Translational Insight

  2026-08-31

  U 46619, also known as 11,9 epoxymethano-prostaglandin H2, is a selective TP-receptor agonist that converts receptor activation into measurable platelet, vascular, renal, and blood-pressure phenotypes. This thought-leadership article places the compound within a translational framework, showing how concentration-dependent biology, orthogonal readouts, and careful separation from clinical anticoagulation can strengthen preclinical decision-making.

• Dual HER2–VEGFR-2 Targeting in Breast Cancer

  2026-08-30

  The 2026 reference study examines whether combining Lapatinib with the VEGFR tyrosine kinase inhibitor Telatinib can suppress invasive and angiogenic phenotypes in the HER2-negative MDA-MB-231 triple-negative breast cancer model. Its main contribution is a phenotype-first evaluation linking reduced invadopodia, cell proliferation, and two-dimensional tube formation to a potential HER-2/VEGFR-2 dual-targeting strategy, while also highlighting the need to distinguish functional drug response from direct receptor engagement.

• TAI-1: Hec1 Inhibitor Mechanism and Evidence

  2026-08-29

  TAI-1 is a potent small molecule Hec1 inhibitor that disrupts Hec1–Nek2 signaling, promotes mitotic errors, and induces apoptotic cell death in cancer models. Product data report a GI50 of 13.48 nM in K562 cells, while broader efficacy, biomarker, combination, and safety findings remain preclinical.

• Primidone and hPON1: Inhibition Study Insights

  2026-08-28

  The reference study purified human serum paraoxonase-1 and compared its inhibition by five antiepileptic drugs, identifying Primidone as a noncompetitive hPON1 inhibitor with an intermediate potency among the compounds tested. These findings broaden interpretation of antiepileptic drug biology and provide a biochemical basis for examining possible links between AED exposure, oxidative protection, and cardiovascular risk in epilepsy.

• Adipose-Neural Signaling in Cardiac Arrhythmia

  2026-08-28

  Fan et al. developed a stem cell-based coculture model showing that epicardial adipose tissue can activate sympathetic neurons through leptin and drive NPY/Y1R-dependent electrical instability in cardiomyocytes. The study connects this adipose-neural axis to NCX and CaMKII activity and supports its clinical relevance through EAT and coronary sinus blood measurements in patients with atrial fibrillation.

• Streptavidin-FITC for Mechanistic LNP Translation

  2026-08-27

  Streptavidin-FITC is more than a fluorescent tag: used strategically, it can help translational researchers connect biotinylated LNP disposition with surface charge, endo/lysosomal biology, and functional nucleic acid delivery. This thought-leadership guide outlines the mechanistic opportunity, validation framework, workflow parameters, competitive positioning, and limitations of applying fluorescein isothiocyanate conjugated streptavidin to delivery research.

• Demethyleneberberine in Con A–Induced Autoimmune Hepatitis

  2026-08-27

  The reference study showed that Demethyleneberberine (DMB) reduced concanavalin A-induced liver injury in mice while suppressing inflammatory-cell infiltration, cytokine production, oxidative stress, and activation of NF-κB and MAPK signaling. Its value is primarily mechanistic and preclinical: the work positions DMB as a candidate anti-autoimmune hepatitis agent, while also defining measurable endpoints for follow-up studies.

8076 records 1/539 page Next 12345 下5页 Last page